Experimental drug shows promise for rare melanoma type

NCT ID NCT02975700

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-stage study tested an experimental drug called PLX3397 in 6 people with advanced melanoma that has a specific KIT gene mutation and cannot be removed by surgery. The goal was to check the drug's safety and see if it could shrink tumors. While some patients had their tumors shrink or stabilize, the study was small and more research is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

  • Samsung Medical Center

    Seoul, Gangnam-Gu, 06351, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, Seodaemun-gu, 03722, South Korea

  • Sun Yat-sen Hospital

    Guangzhou, Guangdong, China